Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models

Area of Science:

• Cardiology
• Nanomedicine
• Pharmacology

Background:

• Botulinum toxin type A (BoNT/A1) shows potential for treating atrial fibrillation via autonomic blockade.
• Previous assessments of BoNT's antiarrhythmic properties were limited to specific models.
• A need exists for evaluating novel formulations and broader arrhythmia models.

Purpose of the Study:

• To investigate the antiarrhythmic efficacy of botulinum toxin A1-chitosan nanoparticles (BTN).
• To assess BTN's effects in multiple rat models of induced cardiac arrhythmia.
• To determine if BTN enhances the antiarrhythmic action of BoNT/A1.

Main Methods:

• Formulation of botulinum toxin A1-chitosan nanoparticles (BTN).
• Induction of arrhythmias in rat models using calcium chloride, barium chloride, and electrical stimulation.
• Evaluation of antiarrhythmic effects following subepicardial injection of BTN.

Main Results:

• BTN formulation demonstrated enhanced antiarrhythmic properties compared to BoNT/A1 alone.
• Subepicardial injection of BTN yielded significant antiarrhythmic effects across all tested rat models.
• BTN effectively antagonized arrhythmias induced by the activation of calcium (Ca), potassium (K), and sodium (Na) channels.

Conclusions:

• Botulinum toxin A1-chitosan nanoparticles (BTN) possess significant antiarrhythmic capabilities.
• BTN represents a promising therapeutic strategy for managing cardiac arrhythmias, including atrial fibrillation.
• The nanoparticle formulation enhances BoNT/A1's efficacy in modulating ion channel-dependent arrhythmias.